Our 2020 Blueprint
2
marketed products
4
pending
marketing
applications
marketing
applications
6
clinical-stage
therapeutic
candidates
therapeutic
candidates
8
research
programs
programs
Our “2020 Blueprint” strategy establishes a planned path to transform Blueprint Medicines, by the end of 2020, into a global commercial enterprise focused on delivering a portfolio of precision therapies to patients with cancer and rare diseases. See our press release.
Recent News
Apr 05, 2021
Blueprint Medicines to Host Virtual Investor Event and Webcast to Review New Data Presented at AACR Annual Meeting on Monday, April 12, 2021
Events and presentations
Apr 12, 2021
Blueprint Medicines AACR Conference Call
Mar 10, 2021
Blueprint Medicines to Present at Barclays Global Healthcare Conference
Our commitment to patients
At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve the lives of people with genomically defined diseases.
Read onPhoto: R.T., living with gastrointestinal stromal tumor
Clinical programs
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.
Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.
Meet the Blue Crew
Meet the Blue Crew
Andrew Kim, International Launch Lead and General Manager, Nordics
As Blueprint Medicines’ International Launch Lead and General Manager, Nordics, my role is to strategically plan and lead outreach to clinical investigators, healthcare providers and laboratories outside the United States to support the company’s portfolio of clinical-stage programs.
Read onWe aspire to pioneer multiple new scientific advances in disease biology and the design of precision therapies. To learn more about our scientific leadership and perspectives, visit The Lens.
Read on
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”Jeff Albers,
Chief Executive Officer
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”Jeff Albers, Chief Executive Officer
Dare to be different
We believe diversity is the key to unlocking our full potential. We push boundaries and take well-calculated risks, committing courageously and wholeheartedly to what we believe in.
Read on